arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

MoonLake Immunotherapeutics

MLTX

$18.25 ▲ +0.24 (+1.36%) at close

23 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

MoonLake Immunotherapeutics faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -15.7% ↘

FCF / Share $-0.93

Trailing P/E —

Price / Book 5.1x

FCF Yield —

Debt / Equity 0.39

info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-69.71M

↓ -74.5% —

FCF / Share Free cash flow per share

$-0.93

↓ -54.1% —

Long-Term Debt Long-term obligations

$99.02M

↑ +33.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
EPS Growth YoY (%)	-55.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-27.8% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-96.4% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-123.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-186.4% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-620.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-211.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-69.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	4.3% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	76.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	32.4% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	92.7% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	—	89.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	88.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-74.5% Weak ↑ Weak Improving Year-over-year change in net income	-36.9% Weak ↑ Weak Improving Year-over-year change in net income	-97.0% Weak ↑ Weak Improving Year-over-year change in net income	-127.6% Weak ↑ Weak Improving Year-over-year change in net income	-192.1% Weak ↑ Weak Improving Year-over-year change in net income	-513.2% Weak ↓ Weak Declining Year-over-year change in net income	-275.5% Weak ↓ Weak Declining Year-over-year change in net income	-139.3% Weak ↓ Weak Declining Year-over-year change in net income	-51.8% Weak ↓ Weak Declining Year-over-year change in net income	56.5% Excellent ↑ Excellent Improving Year-over-year change in net income	6.8% Fair ↓ Fair Declining Year-over-year change in net income	16.3% Good ↑ Good Improving Year-over-year change in net income	43.3% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-60.8% Weak ↑ Weak Improving Year-over-year change in net income	62.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-20715.2% Weak Weak Year-over-year change in net income	—	-125661.1% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	-54.1% Weak Weak Year-over-year change in free cash flow	—	—	—	-149.4% Weak Weak Year-over-year change in free cash flow	—	—	—	-4.8% Weak Weak Year-over-year change in free cash flow	—	—	—	91.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	1.11x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.70x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.41x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Return on Invested Capital (%)	-15.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-2.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	-2.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-2.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	-21.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-388.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	-1.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-17.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-3.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-2.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-2.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-16.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	30.0% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—	-0.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-27.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-283%)	-20.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-237%)	-24.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-15.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-204%)	-9.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-165%)	-10.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-168%)	-7.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-148%)	-4.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-2.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-117%)	—	-2.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-115%)	-2.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-114%)	-21.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	—	-18.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-222%)	-19.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-227%)	—	—	—	—	-1.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-110%)	—	-25.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-267%)

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Debt to Equity (x)	0.39x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-35%)	0.24x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-59%)	0.26x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-57%)	0.21x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-65%)	0.18x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-70%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—	—	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—	—	—
Interest Coverage (x)	-38.50x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-29.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-41.65x Weak Weak Operating income divided by interest expense Optimal: > 5x	-52.51x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-199.47M	$-260.42M	$-277.00M	$-233.30M	$-198.54M	$-180.43M	$-375.66M	$-342.79M	$-458.44M	—	$-318.17M	$-501.79M	$-50.13M	—	$-41.20M	$0.00	—	$-666.79K	—	—	$-1.17M	$-1.34M	—
Debt / EBITDA (x)	-1.43x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.15x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.04x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.22x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.55x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Basic EPS, GAAP (USD)	$-0.98	$-0.92	$-1.10	$-0.87	$-0.63	$-0.72	$-0.56	$-0.39	$-0.22	$-0.10	$-0.18	$-0.23	$-0.23	$-0.43	$-0.27	$-0.34	$-3.17	—	$-2.63	$-2.90	—	—	—
Free Cash Flow per Share (USD)	$-0.93	—	$-0.70	$-0.86	$-0.60	—	—	—	$-0.24	—	—	—	$-0.23	—	—	—	$-2.83	—	$-0.85	$-2.27	—	—	—
Book Value per Share (USD)	$3.56	—	$4.56	$5.59	$6.44	—	$7.76	$8.28	$8.66	—	$7.94	$11.20	$1.08	—	$1.50	$1.80	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$3.56	—	$4.56	$5.59	$6.44	—	$7.76	$8.28	$8.66	—	$7.94	$11.20	$1.08	—	$1.50	$1.80	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	71.27M	—	63.37M	63.28M	63.23M	—	62.90M	62.87M	62.64M	—	53.52M	43.72M	39.06M	—	36.93M	35.20M	5.01M	—	2.39M	11.28M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Working Capital (USD)	$350.53M	$376.22M	$362.85M	$428.12M	$482.28M	$451.83M	$492.24M	$524.60M	$544.68M	—	$489.70M	$499.23M	$59.23M	—	$82.52M	$94.52M	—	$-3.08M	—	—	$1.40M	$1.49M	—
LT Debt (USD)	$99.02M	$74.10M	$73.74M	$73.38M	$73.02M	$0.00	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Equity (USD)	$254.02M	$304.48M	$288.91M	$353.73M	$407.52M	$446.82M	$488.20M	$520.66M	$542.55M	—	$424.93M	$489.80M	$42.00M	—	$55.29M	$63.51M	—	$-7.06M	—	—	$5.00M	$-2.52M	$20.00K

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Depreciation Expense (USD)	$845.00K	$751.00K	$745.00K	$742.00K	$378.00K	$364.00K	$32.52K	$28.11K	$22.81K	—	—	—	$3.29K	—	—	—	$2.49K	—	$2.27K	—	—	—	—
Net Income, GAAP (USD)	$-69.71M	$-62.43M	$-69.73M	$-55.22M	$-39.94M	$-45.60M	$-35.39M	$-24.27M	$-13.67M	$-7.44M	$-9.43M	$-10.14M	$-9.00M	$-17.11M	$-10.11M	$-12.12M	$-15.88M	$34.78M	$-6.29M	$-32.69M	$-76.29K	—	$-5.00K
Operating Cash Flow (USD)	$-66.29M	$-58.79M	$-44.54M	$-54.53M	$-38.14M	$-48.47M	—	—	$-14.95M	$-12.34M	—	—	$-9.02M	$-11.60M	—	—	$-14.19M	$27.11M	$-2.02M	$-25.60M	$-107.80K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 23 quarters

MoonLake Immunotherapeutics

Analytical Summary

23-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MLTX with peers